X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
23 chronic insomnia patients treated with ZLT-101, Zelira's proprietary and patented medicinal cannabis formulation, demonstrated statistically significant improvement in Insomnia Severity Index.
Lead Product(s): ZLT-101
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
Details:
Zelira Therapeutics is assisting Parkinson’s Foundation in the development of a survey to understand the current use and perceived benefits of medical cannabis among people with PD.
Lead Product(s): Cannabinoid-based Product
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Parkinson’s Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
